Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol

Andre Abitbol; Alan Lewin; Michael Troner

Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol

Andre Abitbol, Alan Lewin, Michael Troner

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	American Journal of Clinical Oncology
Volume	28
State	Published - Oct 1 2005

Access to Document

ViewcontentFinal published version, 20.4 KBLicense: Unspecified

Cite this

Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol. / Abitbol, Andre ; Lewin, Alan; Troner, Michael.
In: American Journal of Clinical Oncology, Vol. 28, 01.10.2005.

Research output: Contribution to journal › Article › peer-review

@article{4d5c62aa80164ecf9f2a0064d85f3609,

title = "Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol",

author = "Andre Abitbol and Alan Lewin and Michael Troner",

note = "American Journal of Clinical Oncology (2005) 28(5):449-55",

year = "2005",

month = oct,

day = "1",

language = "American English",

volume = "28",

journal = "American Journal of Clinical Oncology",

}

TY - JOUR

T1 - Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol

AU - Abitbol, Andre

AU - Lewin, Alan

AU - Troner, Michael

N1 - American Journal of Clinical Oncology (2005) 28(5):449-55

PY - 2005/10/1

Y1 - 2005/10/1

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/2015

M3 - Article

VL - 28

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

ER -

Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol

Access to Document

Other files and links

Cite this